Amarin Corporation PLC Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa™

Published: Oct 23, 2012

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued two patents covering the use of Amarin's VascepaTM (icosapent ethyl) capsules based on U.S. Patent Application Serial Nos. 12/702,889 and 13/349,153, both titled "Methods of Treating Hypertriglyceridemia." On September 5, 2012, Amarin announced the issuance of Notices of Allowance for claims under these applications.

Back to news